Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

NCT05891561 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pertuzumab

Sponsor

Shanghai Jiao Tong University School of Medicine